Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Efficacy and safety of Crizotinib in patients with ALK positive non small cell lung cancer (NSCLC): Real-world findings.
Metastatic Non-Small Cell Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
2019 ASCO Annual Meeting
J Clin Oncol 37, 2019 (suppl; abstr e20636)
Author(s): Cristina Azpitarte Raposeiras, Noemi De Dios Alvarez, Jorge Garcia, Maria Carmen Areses Manrique, Natalia Fernández Núñez, Francisco J. Afonso Afonso, Margarita Amenedo, Nazaret Quiroga Veiga, Victor Cebey, Martin Lazaro Quintela, Jose-luis Firvida, Begoña Campos Balea, Juan Ruiz Bañobre, Vanesa Varela Pose, Sara Agraso Busto, Manuel Constenla; Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain; Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain; Complejo Hospitalario Universitario de Ourense, Ourense, Spain; Hospital Universitario Lucus Augusti, Lugo, Spain; Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario de Pontevedra, Pontevedra, Spain; Complejo Hospitalario Santiago de Compostela, Santiago De Compostela, Spain; Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Ourense, Orense, Spain; Medical Oncology Department. Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain; Servicio de Oncología Médica, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
Background: First or second line crizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with NSCLC ALK positive and it was the first approved ALK inhibitor. However, there are limited data describing the use of crizotinib and its outcomes in real-world settings. Methods: This is a retrospective, observational study of patients crizotinib treated ALK positive metastatic NSCLC, who received treatment between 1 January 2013 and 30 november 2018. The primary objective was progression free survival (PFS); secondary objetives were overall survival (OS), response rates and toxicity. Results: Fifty-eight patients with NSCLC ALK+ were recollected, 33 women and 25 men. The median age was 61 years (25-88); 46.6% were never smokers, 31% were former smokers. The majority (96.6%) had confirmed adenocarcinoma histology and 25.9% had brain metastases at inicial treatment. Crizotinib was used as first line 55.2% and second line in 37.9%. Progression disease was the most frequent reason of discontinuation of crizotinib (74%) and in 5 patients was discontinued because of toxicity. The most frequent toxicities were edemas (37.9%), increased transaminases (27.5), diarrhea (24%) and nauseas (20%). Grade 3-4 toxicities were present in 4 cases with increase transaminases, 1 case of neumonitis and 2 patients with diarrhea. The response rate was 63.8%. The median PFS was 12.66 months (95% CI :7.95- 17.38) and median OS was 23.36 months (95%CI: 16.29-30.44).In patients with brain metastases (15) the response rate was 46.6% and median OS decrease to 15.36 months (95%CI: 0.1-30.8). Conclusions: Our findings indicate that the results of crizotinib in the real world are consistent or sightly improved with prior clinical trial in PFS and OS, despite our sample includes patients for first line and second/later line crizotinib and ¼ of patients had brain metastasic at crizotinib initiation.